News | Radiation Therapy | October 13, 2016

Reduced Radiation Boost Volume Recommended for Primary Tumor Site in Average-Risk Pediatric Medulloblastoma

Children’s Oncology Group trial finds survival not compromised from smaller radiation volume to posterior fossa but upholds standard doses for craniospinal irradiation

pediatric medulloblastoma, brain tumor, radiation therapy, boost volume, clinical study, ASTRO 2016

October 13, 2016 — In the largest trial conducted for average risk (A-R) medulloblastoma, survival rates following reduced radiation therapy (RT) boost volumes were comparable to standard treatment volumes for the primary tumor site. However, lower doses of craniospinal axis irradiation were associated with higher event rates and worse survival, according to research presented at the 58th annual meeting of the American Society for Radiation Oncology (ASTRO), Sept. 25-28 in Boston.

Findings from this phase III randomized trial indicate that physicians can adopt smaller boost volumes for posterior fossa RT but should maintain the standard RT dose for craniospinal irradiation (CSI).

The most common type of brain malignancy in children, medulloblastoma is an aggressive tumor that originates in the lower, rear area of the brain but has a propensity to spread to the upper brain and spine. As a result, the standard of care following surgical resection for these children has included systemic chemotherapy and irradiation to both the posterior fossa (i.e., the primary site) and the craniospinal axis. Complications of craniospinal irradiation, however, include considerable negative effects on patients’ neurocognitive abilities, endocrinologic function and hearing.

Researchers from the National Cancer Institute-supported Children’s Oncology Group conducted this phase III trial to assess outcomes from a reduced radiation boost volume to the posterior fossa among pediatric A-R medulloblastoma patients and a lower CSI dose specifically in younger children. While several single-institution trials have found limited posterior fossa boost to be comparable to whole posterior fossa boost, this is the first trial that was sufficiently powered to state definitively that there is no survival difference between the two approaches.

Findings are based on data from 464 patients ages three to 21 with A-R medulloblastoma. Eligible patients had complete or near-complete resection of their primary tumors and no evidence of anaplasia or spread of the cancer beyond the posterior fossa. Patients were randomized to receive either a standard radiation boost volume to the posterior fossa (PFRT group, n = 237) or a reduced dose of involved field RT (IFRT group, n = 227). The 226 patients who were ages three to seven were also randomized to receive either a standard irradiation dose of 23.4 Gy to the craniospinal axis (SD-CSI group, n = 110) or a reduced dose of 18 Gy (LD-CSI group, n = 116). Following maximum surgery and within 31 days following resection, patients began six weeks of RT. After a one-month break, patients began to receive alternating cycles of Cisplatin- and Cytoxan-based chemotherapy.

Primary outcomes included the amount of time from study entry to disease progression, disease recurrence, death from any cause or second malignant neoplasm. Researchers compared rates of overall survival (OS), event-free survival (EFS), local failure and distant failure by computing Hazard Ratios (HR) and performing intent-to-treat analysis.

With a median follow-up of more than six and a half years, reduction in the volume of RT boost to the posterior fossa did not compromise overall or event-free or survival in pediatric patients with A-R medulloblastoma. Overall survival at five years was 84.1 ± 2.8 percent for patients who received the reduced volume with IFRT and 85.2 ± 2.6 percent for patients who received the standard volume with PFRT. EFS at five years was 82.2 ± 2.9 percent for IFRT and 80.8 ± 3 percent for PFRT. Rates of local failure also did not vary significantly between treatment arms. Local failure at five years was 1.9 ± 0.1 percent for IFRT and 3.7 ± 1.3 percent for PFRT (p = 0.178).

“This trial — the largest of its kind to date — indicates that it is safe to adopt a limited posterior fossa boost for patients receiving radiation therapy for average risk medulloblastoma, and that these children can have similar positive outcomes with lower chances of radiation affecting surrounding brain tissue” said Jeff M. Michalski, M.D., MBA, FASTRO, professor of radiation oncology at Washington University in St. Louis and lead author of the study. “Additional data are needed, however, to address the appropriate volume for patients with higher risk disease or those who have metastasis at the time of diagnosis.”

While reduced RT volume to the posterior fossa did not impact survival rates, a low dose of craniospinal irradiation was associated with lower rates of event-free and overall survival for the youngest pediatric patients. Overall survival at five years was 78.1 ± 4.4 percent for patients ages three to seven who received low-dose irradiation therapy to the CSI versus 85.9 ± 3.8 percent for the standard CSI dose. EFS at five years was 72.1 ± 4.8 percent for the LD-CSI group, compared to 82.6 ± 4.2 percent for SD-CSI. Rates of distant failure did not vary significantly between treatment groups. Isolated distant failure at five years was 12.8 ± 3.2 percent for LD-CSI and 8.2 ± 2.8 percent for SD-CSI (p = 0.115).

“Unfortunately, we were disappointed to find that a lower dose of irradiation therapy was associated with increased rate of failure in the younger children,” said Michalski. “Reducing the treatment by just three fractions from 23.4 Gy to 18 Gy was associated with a higher rate of events and diminished overall survival. Patients with average-risk medulloblastoma should continue to receive a standard dose of 23.4 Gy to the craniospinal axis, unless they are enrolled in a clinical trial.”

For more information: www.astro.org

Related Content

RayStation Replacing Existing Treatment Planning System at Leeds Cancer Centre
News | Treatment Planning | September 24, 2018
RaySearch recently strengthened its position in the U.K. market with a major order for the treatment planning system...
Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...